explore -WSS

explore

author：leisure time 2025-09-28 00:47:48 - browse：89218

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

leisure time

WSS

Cytokinetics CEO stresses company can launch heart drug on its own

Why Charlie Gard's case is so disturbing to Americans

Readers respond to H5N1 and livestock movements, and more

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Arc Institute generative AI designs new CRISPR systems

Why age limits for politicians are a terrible idea

knowledge

explore

hotspot

Virginia high school admissions case could be legal follow

When prostate cancer spreads, where it goes matters

BioMarin wins approval for gene therapy to treat hemophilia A

Solving academic medical centers' existential crisis

Medical leaders decry Supreme Court decision on affirmative action

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Guidelines to prevent youth baseball injuries need more muscle

A virus, fished out of a lake, may have saved a man’s life

Medical records are filled with copy

Cytokinetics CEO stresses company can launch heart drug on its own

entertainment

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Senate panel eyes new effort on drug shortages

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

When women are denied an abortion, their children fare worse than peers

Bristol 'take

focus

focus

leisure time

explore